Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Payables (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Payables for 6 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Payables rose 133.56% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, up 133.56% year-over-year, with the annual reading at $5.8 million for FY2025, 133.56% up from the prior year.
  • Payables for Q4 2025 was $5.8 million at Caribou Biosciences, up from $3.8 million in the prior quarter.
  • The five-year high for Payables was $5.9 million in Q1 2024, with the low at $426000.0 in Q2 2022.
  • Average Payables over 5 years is $3.1 million, with a median of $3.2 million recorded in 2024.
  • The sharpest move saw Payables plummeted 89.43% in 2022, then skyrocketed 940.61% in 2023.
  • Over 5 years, Payables stood at $4.0 million in 2021, then tumbled by 71.28% to $1.1 million in 2022, then soared by 172.25% to $3.1 million in 2023, then fell by 20.64% to $2.5 million in 2024, then surged by 133.56% to $5.8 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $5.8 million, $3.8 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.